The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) is a large international collaboration to develop algorithms using a set of clinical and cognitive assessments, multi-modal biomarkers, and clinical endpoints that can be used to predict the trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the testing of pharmacological interventions for CHR individuals in need. The goal is to accurately predict which individuals are likely to remit, experience an acute psychotic episode, or have intermediate outcomes that feature persistent attenuated psychotic and/or mood symptoms along with functional impairment. The prediction algorithms will have the potential to serve as early indicators of treatment efficacy in CHR persons.
The AMP SCZ research program is made up of the Psychosis Risk Evaluation, Data Integration, and Computational Technologies - Data Processing, Analysis and Coordination Center (PREDICT-DPACC) and two clinical research networks, the Psychosis-Risk Outcomes Network (ProNET) and the Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium (PRESCIENT) networks. The two clinical research networks will recruit a large cohort of CHR young people aged 12-30 years (n=1,977) and healthy control (HC) participants (n=640) across 42 participating investigative sites from 13 countries. CHR participants will complete screening, baseline assessments and a battery of follow-up assessments across 18 - 24 months. HC participants will complete screening and baseline assessments and a subset (5 per site) will complete month 2, 12 and 24 visits.
| Facility | City | Region | Status |
|---|---|---|---|
| University of California Irvine | Irvine | California | |
| University of California Los Angeles | Los Angeles | California | |
| University of California San Diego | San Diego | California | |
| University of California San Francisco | San Francisco | California | |
| Hartford Healthcare | Hartford | Connecticut | |
| Yale University/Connecticut Mental Health Center | New Haven | Connecticut | |
| University of Georgia | Athens | Georgia | |
| Northwestern University | Evanston | Illinois | |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | |
| Washington University | St Louis | Missouri | |
| Icahn School of Medicine at Mount Sinai | New York | New York | |
| Northwell Health | Queens | New York | |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | |
| University of Oregon | Eugene | Oregon | |
| University of Pennsylvania | Philadelphia | Pennsylvania | |
| Temple University | Philadelphia | Pennsylvania | |
| University of Pittsburgh | Pittsburgh | Pennsylvania | |
| HEP and co-located Headspace Adelaide | Adelaide | South Australia | |
| Headspace, Craigieburn | Craigieburn | Victoria | |
| Headspace, Glenroy | Glenroy | Victoria | |
| Headspace Melton | Melton South | Victoria | |
| Orygen Specialist Programs, Melbourne | Parkville | Victoria | |
| Headspace, Sunshine | Sunshine | Victoria | |
| Headspace, Werribee | Werribee | Victoria | |
| University of Calgary | Calgary | Alberta | |
| McGill University | Montreal | Quebec | |
| Hospital Clínico Universidad de Chile (HCUCH) | Santiago | Santiago Metropolitan | |
| Shanghai Jiao Tong University | Shanghai | China | |
| Copenhagen Research Center for Mental Health (CORE) | Copenhagen | Denmark | |
| Klinik für Psychiatrie und Psychotherapie, University of Cologne | Cologne | Brescia | |
| The University Hospital Jena, Department of Psychiatry | Jena | Thuringia | |
| Ludwig-Maximilians-Universität Munich | Munich | Germany | |
| The University of Hong Kong, Department of Psychiatry | Hong Kong | Hong Kong | |
| University of Pavia | Pavia | Pavia | |
| Early Psychosis Intervention Programme (EPIP) Clinic, Institute of Mental Health | Singapore | Singapore | |
| Department of Psychiatry, Chonnam National University Hospital & Mindlink | Gwangju | South Korea | |
| Seoul National University College of Medicine | Seoul | South Korea | |
| Instituto de Psiquiatría y Salud Mental Hospital General Universitario Gregorio Marañón | Madrid | Spain | |
| Treatment and Early Intervention in Psychosis Program (TIPP) & Center for Psychiatric Neuroscience (CNP), Department of Psychiatry, Lausanne University Hospital | Lausanne | Switzerland | |
| Forward Thinking Birmingham | Birmingham | United Kingdom |
+ 2 more sites — see the full list on the official registry below.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05905003 on ClinicalTrials.gov ↗ ← All trials in Canada